OS Therapies (NYSE:OSTX) Shares Up 35.3% – What’s Next?

OS Therapies Inc (NYSE:OSTX) shares were up 35.3% during trading on Tuesday . The company traded as high as $6.48 and last traded at $4.71. Approximately 668,717 shares were traded during mid-day trading, an increase of 408% from the average daily volume of 131,554 shares. The stock had previously closed at $3.48.

Wall Street Analyst Weigh In

OSTX has been the subject of a number of recent research reports. Maxim Group initiated coverage on OS Therapies in a research report on Tuesday, November 26th. They set a “buy” rating and a $8.00 target price for the company. EF Hutton Acquisition Co. I raised OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd. Finally, Brookline Capital Management raised shares of OS Therapies to a “strong-buy” rating in a research note on Thursday, August 22nd.

OS Therapies Stock Performance

The company’s 50-day simple moving average is $2.64.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new stake in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.